

# Completion of CMC, GLP-tox Testing, Clinical Trial Medication Production, and IND Approval for Orally Administerable CD39 Target Inhibitor Preclinical Candidate Substance


SCBIO Inc.

<b>Disease Area</b>	<b>Neoplasm</b>
<b>Product Type</b>	Small Molecule
<b>Indication</b>	Solid cancer, Pancreatic Cancer
<b>Target</b>	CD39
<b>Mechanism of Action</b>	Potent anti-tumor effect through boosting of anti-tumoral immunity in Tumor-associated microenvironment
<b>Competitiveness</b>	Down stream target of ATP/ADO signal axis, CD73 inhibitors such as Quemlistat (clinical phase 1b,, ) Superiority of CD39 as drug target compared to CD73
<b>Development Stage</b>	Currently under CMC development, In this year (2024), it will be entered to GLP-tox for 2025 clinical trial
<b>Route of Administration</b>	Oral administration

Home phage: <http://www.sc-bio.co.kr/>

Key MOA:

ATP/ADO signal axis regulation Drug candidate, SCB001 (CD39 inhibitor)



Anti-cancer immunity boosting mechanism of SCB001

Key Data

- Inflammation, pain, danger signal
- Phagocytosis and immunogenicity
- Platelet aggregation
- Antiproliferative effects

- Anti-inflammatory effects
- Immunosuppression
- Angiogenesis
- Cell proliferation & metastasis